Summary

Global Colorectal Cancer Screening and Diagnostics Market Overview

The global colorectal cancer screening and diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was $37,145.8 million, which is expected to reach $48,710.9 million by 2033, growing at a CAGR of 2.37% during the forecast period. This growth can be attributed to the rising incidence of colorectal cancer and increasing financial burden on healthcare, growing demand for colorectal cancer testing, advances in genomics and molecular diagnostics, and promoting early cancer detection to enable reduced treatment costs. The market includes various types of tests, such as stool DNA tests, fecal immunochemical tests, fecal occult blood tests, biomarker tests, colonoscopies, and sigmoidoscopies.

Market Lifecycle Stage

The colorectal cancer screening and diagnostics market is currently at a growing stage with a robust growth trajectory, propelled by the rising demand for at-home colorectal cancer screening and diagnostics. The market is characterized by a mix of well-established companies and innovative startups, all competing to offer advanced solutions that cater to the evolving demands of research and diagnostics.

Industry Impact

The global colorectal cancer screening and diagnostics market’s impact is profound and multifaceted, influencing healthcare practices, patient outcomes, and economic dynamics within the healthcare sector. The market's growth is driving a significant shift toward early detection and prevention, leading to improved survival rates and quality of life for patients. This shift is also catalyzing a transition in healthcare focus from treatment to prevention, encouraging the development of public health policies and insurance coverage that support regular screening.

Economically, the expansion of the colorectal cancer screening and diagnostics market has been contributing to the healthcare industry's growth, owing to increased investments in research and development of more accurate and less invasive screening technologies. These innovations not only enhance patient compliance and comfort but also have the potential to reduce long-term healthcare costs by preventing advanced disease stages that require more intensive and expensive treatments.

The global colorectal cancer screening and diagnostics market continues to drive transformative advancements across industries, with far-reaching implications for human health and environmental sustainability.

Market Segmentation

Segmentation 1: by Type
• Stool DNA Test
• Fecal Immunochemical Test (FIT)
• Fecal Occult Blood Test (FOBT)
• Colonoscopies and Sigmoidoscopies
• Biomarkers Test

Colonoscopies and Sigmoidoscopies to Dominate the Global Colorectal Cancer Screening and Diagnostics Market (by Type)

Based on type, the colonoscopies and sigmoidoscopies segment dominated the global colorectal cancer screening and diagnostics market in FY2022. This category includes colonoscopes and sigmoidoscopes, which are considered a gold standard for diagnosis and screening for colorectal cancer. Colonoscopy allows for a detailed examination of the entire colon and rectum, enabling the detection of not only cancers but also precancerous polyps, which can be removed during the same procedure to prevent cancer development. Sigmoidoscopy, while more limited in scope, examining only the lower part of the colon, still plays a crucial role in screening efforts, especially in cases where a full colonoscopy might not be necessary or feasible.

Segmentation 2: by End User
• Hospitals and Clinics
• Ambulatory Centers
• Clinical Laboratories
• Others

Hospitals and Clinics Segment to Hold its Dominance in the Global Colorectal Cancer Screening and Diagnostics Market (by End User)

Based on end user, the hospitals and clinics accounted for the largest share of the global colorectal cancer screening and diagnostics market in FY2022 due to the comprehensive healthcare services offered by them, including advanced diagnostic facilities and the availability of specialized care, which enable early detection and management of colorectal cancer.

Segmentation 3: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The North America region is a leader in the global colorectal cancer screening and diagnostics market, a position it is expected to maintain over the coming years. This dominance can be attributed to several key factors, including high awareness levels regarding colorectal cancer, and the implementation of comprehensive screening programs across the U.S. and Canada.

Recent Developments in the Global Colorectal Cancer Screening and Diagnostics Market

• In February 2024, Exact Sciences Corporation announced gearing up for the launch of a new slate of assays over the next few years, including a new iteration of its well-established stool-based colorectal cancer screening test, Cologuard, a complementary blood-based assay and a test for minimal residual disease detection.
• In February 2024, Freenome Holdings, Inc. announced that it raised $254 million in a new funding round led by Swiss drugmaker Roche to develop tests that could potentially detect multiple early-stage cancers and is currently developing screening tests focused on colorectal and lung cancers.
• In May 2023, Guardant Health collaborated with the Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence.
• In May 2023, Guardant Health submitted a premarket approval application to the U.S. Food and Drug Administration for a Shield blood test.
• In April 2023, Mainz Biomed revealed a collaboration with the Instituto de Microecologia aimed at broadening ColoAlert's commercial reach in both Spain and Portugal.
• In May 2023, Olympus Corporation introduced the CF-HQ1100DL/I colon videoscope, a device specifically created for the inspection of the lower digestive system, covering areas such as the anus, rectum, sigmoid colon, colon, and ileocecal valve. This launch would serve to enhance Olympus's range of products within the colorectal cancer screening and diagnostics sector.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare: The increasing healthcare expenditure related to colorectal cancer reflects the growing costs associated with its prevention, diagnosis, treatment, and management. As the incidence of colorectal cancer rises, the economic burden of the disease is also increasing. These costs include direct medical costs such as hospitalization, surgery, chemotherapy, and radiation therapy.

Market Restraints:

Limited Sensitivity of FIT/FOBT Testing Kits: While non-invasive testing techniques for colorectal cancer, such as fecal immunochemical tests and stool DNA tests, have shown significant potential in cancer detection, they do have some limitations. One of the major limitations is their limited sensitivity, meaning they may not detect all cases of colorectal cancer, particularly in the early stages. This can result in false negatives and delayed diagnosis, which can impact patient outcomes.

Market Opportunities:

Expansion of Screening Programs: Population-wide screening programs are proving to be a lucrative opportunity for the colorectal cancer screening and diagnostic market by leading to an increased number of individuals being screened for colorectal cancer, leading to earlier detection and treatment of the disease. By improving access to screening, these programs can also reduce healthcare costs and improve patient outcomes associated with more advanced stages of the disease, thereby resulting in a strong interest in these testing methodologies by various government and NGO screening programs.

How can this report add value to an organization?

Workflow/Innovation Strategy: The global colorectal cancer screening and diagnostics market (by product) has been segmented into detailed segments, including different types of tests, such as fecal immunochemical tests, fecal occult tests, stool DNA tests, biomarker tests, and colonoscopies and sigmoidoscopies.

Growth/Marketing Strategy: A strategic growth and marketing approach for the colorectal cancer screening and diagnostics market would involve positioning the company as a leader in innovative solutions that address the evolving needs of hospitals, clinicians, laboratories, and pharmaceutical partners. This would entail leveraging technological advancements to develop products with enhanced sensitivity and specificity while also investing in comprehensive, collaborative partnerships to foster customer loyalty and drive market penetration.

Competitive Strategy: Key players in the global colorectal cancer screening and diagnostics market have been focusing on innovation, differentiation, and strategic collaborations to gain a competitive edge. By investing in research and development, companies can develop novel screening and diagnostics methods, improve test sensitivity, and expand application areas.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
• The geographical distribution of the market revenue has been estimated to be the same as the company’s net revenue distribution. All the numbers have been adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR has been calculated from 2023 to 2033.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of types of tests for the global colorectal cancer screening and diagnostics market have been considered and profiled in the report.
• In the study, the primary respondent’s verification has been considered to finalize the estimated market for the global colorectal cancer screening and diagnostics market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company, if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report’s segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, and World Health Organization (WHO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

In the colorectal cancer screening and diagnostics market, several key players dominate the landscape with their diverse range of products and solutions. Exact Sciences Corporation, Danaher Corporation, Guardant Health, Inc., Mainz Biomed NV, and New Horizon Health are among the prominent market players offering tests and colonoscopies and sigmoidoscopies for colorectal cancer screening and diagnostics within the market.

The competition in the colorectal cancer screening and diagnostics market has been characterized by a dynamic and intensely competitive landscape with a variety of market players. This competition has been further fuelled by factors such as technological advancements, increasing demand for early detection methods, and the presence of numerous companies offering innovative solutions and services in this field.

Some of the prominent companies in this market are:

• DiaCarta, Inc.
• Danaher Corporation
• Epigenomics AG
• Eiken Chemical Co., Ltd.
• Exact Sciences Corporation
• Freenome Holdings, Inc.
• FUJIFILM Holdings Corporation
• Guardant Health, Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Mainz Biomed NV
• New Horizon Health
• Novigenix SA
• Prenetics Global Limited
• Olympus Corporation
• HOYA Corporation
• QuidelOrtho Corporation

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Rise of At-Home Colorectal Cancer Screening
1.1.2 Multimodal Approaches to Colorectal Cancer Screening
1.1.3 Use of Gut Microbiota in Colorectal Cancer Diagnosis
1.2 Research and Development Review
1.2.1 Patent Filing Trend (by Country, by Year)
1.3 Impact Analysis for Key Global Events: COVID-19
1.3.1 Pre-COVID-19 Phase
1.3.2 During-COVID-19 Phase
1.3.3 Post-COVID-19 Phase
1.4 Product Pipeline
1.5 Regulatory Landscape
1.6 Reimbursement Scenarios in Different Countries and Regions
1.6.1 Stool DNA Test
1.6.2 Fecal Immunochemical Test (FIT)
1.6.3 Fecal Occult Blood Test (FOBT)
1.6.4 Colonoscopies and Sigmoidoscopies
1.6.5 Biomarker Tests
1.7 Pricing Analysis for Different Test Types in Different Regions
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.1.1 Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare
1.8.1.2 Growing Demand for Colorectal Cancer Testing
1.8.1.3 Advances in Genomics and Molecular Diagnostics
1.8.1.4 Earlier Cancer Detection Enabling Reduced Treatment Cost
1.8.2 Market Restraints
1.8.2.1 Limited Sensitivity of FIT/FOBT Testing Kits
1.8.2.2 Challenges with Sample Collection
1.8.3 Market Opportunities
1.8.3.1 Expansion of Screening Programs
1.8.3.2 Markets Proposing Significant Untapped Potential
2 Application
2.1 Application Segmentation
2.2 Application Summary
2.2.1 Application Summary
2.2.2 End User Summary
2.2.2.1 Analyst View
2.3 Global Colorectal Cancer Screening and Diagnostics Market (by End User)
2.4 Overview
2.4.1 Hospitals and Clinics
2.4.2 Ambulatory Centers
2.4.3 Clinical Laboratories
2.4.4 Others
3 Products
3.1 Product Segmentation
3.2 Product Summary
3.2.1 Analyst View
3.3 Global Colorectal Cancer Screening and Diagnostics Market (by Type)
3.3.1 Market Overview
3.3.2 Stool DNA Test
3.3.2.1 Pricing Analysis
3.3.2.2 Competitive Analysis
3.3.2.3 Test Volume
3.3.2.4 Market Sizing and Forecast
3.3.3 Fecal Immunochemical Test (FIT)
3.3.3.1 Pricing Analysis
3.3.3.2 Competitive Analysis
3.3.3.3 Test Volume
3.3.3.4 Market Sizing and Forecast
3.3.4 Fecal Occult Blood Test (FOBT)
3.3.4.1 Pricing Analysis
3.3.4.2 Competitive Analysis
3.3.4.3 Test Volume
3.3.4.4 Market Sizing and Forecast
3.3.5 Colonoscopies and Sigmoidoscopies
3.3.5.1 Pricing Analysis
3.3.5.2 Test Volume
3.3.5.3 Market Sizing and Forecast
3.3.6 Biomarkers Test
3.3.6.1 Pricing Analysis
3.3.6.2 Competitive Analysis
3.3.6.3 Test Volume
3.3.6.4 Market Sizing and Forecast
4 Region
4.1 Regional Summary
4.2 Drivers and Restraints
4.3 North America
4.3.1 Regional Overview
4.3.2 Driving Factors for Market Growth
4.3.3 Factors Challenging the Market
4.3.4 Application
4.3.5 Product
4.3.6 U.S.
4.3.7 Test Volume
4.3.8 Market Sizing and Forecast
4.3.9 Canada
4.3.10 Test Volume
4.3.11 Market Sizing and Forecast
4.4 Europe
4.4.1 Regional Overview
4.4.2 Driving Factors for Market Growth
4.4.3 Factors Challenging the Market
4.4.4 Application
4.4.5 Product
4.4.6 France
4.4.7 Driving Factors for Market Growth
4.4.8 Factors Challenging the Market
4.4.9 Test Volume
4.4.10 Market Sizing and Forecast
4.4.11 Germany
4.4.12 Driving Factors for Market Growth
4.4.13 Factors Challenging the Market
4.4.14 Test Volume
4.4.15 Market Sizing and Forecast
4.4.16 U.K.
4.4.17 Driving Factors for Market Growth
4.4.18 Factors Challenging the Market
4.4.19 Test Volume
4.4.20 Market Sizing and Forecast
4.4.21 Spain
4.4.22 Driving Factors for Market Growth
4.4.23 Factors Challenging the Market
4.4.24 Test Volume
4.4.25 Market Sizing and Forecast
4.4.26 Italy
4.4.27 Driving Factors for Market Growth
4.4.28 Factors Challenging the Market
4.4.29 Test Volume
4.4.30 Market Sizing and Forecast
4.4.31 Rest-of-Europe
4.4.32 Driving Factors for Market Growth
4.4.33 Factors Challenging the Market
4.4.34 Test Volume
4.4.35 Market Sizing and Forecast
4.5 Asia-Pacific
4.5.1 Regional Overview
4.5.2 Driving Factors for Market Growth
4.5.3 Factors Challenging the Market
4.5.4 Application
4.5.5 Product
4.5.6 China
4.5.7 Driving Factors for Market Growth
4.5.8 Factors Challenging the Market
4.5.9 Test Volume
4.5.10 Market Sizing and Forecast
4.5.11 India
4.5.12 Driving Factors for Market Growth
4.5.13 Factors Challenging the Market
4.5.14 Test Volume
4.5.15 Market Sizing and Forecast
4.5.16 Australia
4.5.17 Driving Factors for Market Growth
4.5.18 Factors Challenging the Market
4.5.19 Test Volume
4.5.20 Market Sizing and Forecast
4.5.21 Japan
4.5.22 Driving Factors for Market Growth
4.5.23 Factors Challenging the Market
4.5.24 Test Volume
4.5.25 Market Sizing and Forecast
4.5.26 South Korea
4.5.27 Driving Factors for Market Growth
4.5.28 Factors Challenging the Market
4.5.29 Test Volume
4.5.30 Market Sizing and Forecast
4.5.31 Rest-of-Asia-Pacific
4.5.32 Driving Factors for Market Growth
4.5.33 Factors Challenging the Market
4.5.34 Test Volume
4.5.35 Market Sizing and Forecast
4.6 Latin America
4.6.1 Regional Overview
4.6.2 Driving Factors for Market Growth
4.6.3 Factors Challenging the Market
4.6.4 Application
4.6.5 Product
4.6.6 Brazil
4.6.7 Driving Factors for Market Growth
4.6.8 Factors Challenging the Market
4.6.9 Test Volume
4.6.10 Market Sizing and Forecast
4.6.11 Mexico
4.6.12 Driving Factors for Market Growth
4.6.13 Factors Challenging the Market
4.6.14 Test Volume
4.6.15 Market Sizing and Forecast
4.6.16 Rest-of-Latin America
4.6.17 Driving Factors for Market Growth
4.6.18 Factors Challenging the Market
4.6.19 Test Volume
4.6.20 Market Sizing and Forecast
4.7 Middle East and Africa
4.7.1 Regional Overview
4.7.2 Driving Factors for Market Growth
4.7.3 Factors Challenging the Market
4.7.4 Application
4.7.5 Product
4.7.6 U.A.E.
4.7.7 Driving Factors for Market Growth
4.7.8 Factors Challenging the Market
4.7.9 Test Volume
4.7.10 Market Sizing and Forecast
4.7.11 South Africa
4.7.12 Driving Factors for Market Growth
4.7.13 Factors Challenging the Market
4.7.14 Test Volume
4.7.15 Market Sizing and Forecast
4.7.16 Rest-of-Middle East and Africa
4.7.17 Driving Factors for Market Growth
4.7.18 Factors Challenging the Market
4.7.19 Test Volume
4.7.20 Market Sizing and Forecast
5 Markets - Competitive Benchmarking & Company Profiles
5.1 Next Frontiers
5.2 Geographic Assessment
5.2.1 DiaCarta, Inc.
5.2.1.1 Overview
5.2.1.2 Top Products/Product Portfolio
5.2.1.3 Top Competitors
5.2.1.4 Key Personnel
5.2.1.5 Analyst View
5.2.2 Danaher Corporation
5.2.2.1 Overview
5.2.2.2 Top Products/Product Portfolio
5.2.2.3 Top Competitors
5.2.2.4 Key Personnel
5.2.2.5 Analyst View
5.2.3 Epigenomics AG
5.2.3.1 Overview
5.2.3.2 Top Products/Product Portfolio
5.2.3.3 Top Competitors
5.2.3.4 Key Personnel
5.2.3.5 Analyst View
5.2.4 Eiken Chemical Co., Ltd.
5.2.4.1 Overview
5.2.4.2 Top Products/Product Portfolio
5.2.4.3 Top Competitors
5.2.4.4 Key Personnel
5.2.4.5 Analyst View
5.2.5 Exact Sciences Corporation
5.2.5.1 Overview
5.2.5.2 Top Products/Product Portfolio
5.2.5.3 Top Competitors
5.2.5.4 Key Personnel
5.2.5.5 Analyst View
5.2.6 Freenome Holdings, Inc.
5.2.6.1 Overview
5.2.6.2 Top Products/Product Portfolio
5.2.6.3 Top Competitors
5.2.6.4 Key Personnel
5.2.6.5 Analyst View
5.2.7 FUJIFILM Holdings Corporation
5.2.7.1 Overview
5.2.7.2 Top Products/Product Portfolio
5.2.7.3 Top Competitors
5.2.7.4 Key Personnel
5.2.7.5 Analyst View
5.2.8 Guardant Health, Inc.
5.2.8.1 Overview
5.2.8.2 Top Products/Product Portfolio
5.2.8.3 Top Competitors
5.2.8.4 Key Personnel
5.2.8.5 Analyst View
5.2.9 Lepu Medical Technology (Beijing) Co., Ltd.
5.2.9.1 Overview
5.2.9.2 Top Products/Product Portfolio
5.2.9.3 Top Competitors
5.2.9.4 Key Personnel
5.2.9.5 Analyst View
5.2.10 Mainz Biomed NV
5.2.10.1 Overview
5.2.10.2 Top Products/Product Portfolio
5.2.10.3 Top Competitors
5.2.10.4 Key Personnel
5.2.10.5 Analyst View
5.2.11 New Horizon Health
5.2.11.1 Overview
5.2.11.2 Top Products/Product Portfolio
5.2.11.3 Top Competitors
5.2.11.4 Key Personnel
5.2.11.5 Analyst View
5.2.12 Novigenix SA
5.2.12.1 Overview
5.2.12.2 Top Products/Product Portfolio
5.2.12.3 Top Competitors
5.2.12.4 Key Personnel
5.2.12.5 Analyst View
5.2.13 Prenetics Global Limited
5.2.13.1 Overview
5.2.13.2 Top Products/Product Portfolio
5.2.13.3 Top Competitors
5.2.13.4 Key Personnel
5.2.13.5 Analyst View
5.2.14 Olympus Corporation
5.2.14.1 Overview
5.2.14.2 Top Products/Product Portfolio
5.2.14.3 Top Competitors
5.2.14.4 Key Personnel
5.2.14.5 Analyst View
5.2.15 HOYA Corporation
5.2.15.1 Overview
5.2.15.2 Top Products/Product Portfolio
5.2.15.3 Top Competitors
5.2.15.4 Key Personnel
5.2.15.5 Analyst View
5.2.16 QuidelOrtho Corporation
5.2.16.1 Overview
5.2.16.2 Top Products/Product Portfolio
5.2.16.3 Top Competitors
5.2.16.4 Key Personnel
5.2.16.5 Analyst View
6 Research Methodology
6.1 Data Sources
6.1.1 Primary Data Sources
6.1.2 Secondary Data Sources
6.1.3 Data Triangulation
6.2 Market Estimation and Forecast
List of Figures
Figure 1: Global Colorectal Cancer Screening and Diagnostics Market, $Million, 2023, 2026, and 2033
Figure 2: Global Colorectal Cancer Screening and Diagnostics Market (by Region), $Million, 2022, 2026, and 2033
Figure 3: Global Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022, 2026, and 2033
Figure 4: Global Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
Figure 5: Key Events to Keep Track of within the Colorectal Cancer Screening and Diagnostics Market
Figure 6: Global Colorectal Cancer Screening and Diagnostics Market (by Country), January 2021-December 2023
Figure 7: Global Colorectal Cancer Screening and Diagnostics Market (by Year), January 2021-December 2023
Figure 8: Colorectal Cancer Cases Diagnosed and Colonoscopies Performed (Pre-Pandemic And During Pandemic), Aragon Spain, March 2020-February 2021
Figure 9: Number of Colorectal Cancer Cases Globally, 2020- 2040
Figure 10: Uptake of FIT Test, U.K., 2019-2022
Figure 11: Cancer Survival Rate with Respect to Stage of Detection, 2022
Figure 12: Stool DNA Test Colorectal Cancer Screening and Diagnostics Market, Competitive Analysis
Figure 13: Stool DNA Test Colorectal Cancer Screening and Diagnostics Market, Test Volume, Unit Thousands, 2022-2033
Figure 14: Stool DNA Test Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 15: FIT Colorectal Cancer Screening and Diagnostics Market, Competitive Analysis
Figure 16: Fecal Immunochemical Test Colorectal Cancer Screening and Diagnostics Market, Test Volume, Unit Thousands, 2022-2033
Figure 17: Fecal Immunochemical Test Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 18: FOBT Colorectal Cancer Screening and Diagnostics Market, Competitive Analysis
Figure 19: Fecal Occult Blood Test Colorectal Cancer Screening and Diagnostics Market, Test Volume, Unit Thousands, 2022-2033
Figure 20: Fecal Occult Blood Test Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 21: Colonoscopies and Sigmoido Test Colorectal Cancer Screening and Diagnostics Market, Test Volume, Unit Thousands, 2022-2033
Figure 22: Colonoscopy and Sigmoidoscopy Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 23: Biomarker Test Colorectal Cancer Screening and Diagnostics Market, Test Volume, Unit Thousands, 2022-2033
Figure 24: Biomarker Tests Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 25: U.S. Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 26: Canada Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 27: France Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 28: Germany Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 29: U.K. Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 30: Spain Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 31: Italy Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 32: Rest-of-Europe Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 33: China Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 34: India Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 35: Australia Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 36: Japan Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 37: South Korea Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 38: Rest-of-Asia-Pacific Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 39: Brazil Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 40: Mexico Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 41: Rest-of-Latin America Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 42: U.A.E. Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 43: South Africa Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 44: Rest-of-Middle East and Africa Colorectal Cancer Screening and Diagnostics Market, $Million, 2022-2033
Figure 45: Strategic Initiatives, 2020-2024
Figure 46: Share of Strategic Initiatives, 2020-2024
Figure 47: Data Triangulation
Figure 48: Top-Down and Bottom-Up Approach
Figure 49: Assumptions and Limitations
List of Tables
Table 1: Market Snapshot
Table 2: Global Colorectal Cancer Screening and Diagnostics Market, Opportunities
Table 3: Colorectal Cancer Screening and Diagnostics Market Trend Analysis
Table 4: Examples of Gut Microbiotia as Biomarker for Colorectal Cancer Screening
Table 5: Global Colorectal Cancer Screening and Diagnostic Market, Product Pipeline
Table 6: Reimbursement of Stool DNA Test (by Country)
Table 7: Reimbursement of Fecal Immunochemical Test (by Country)
Table 8: Reimbursement of Fecal Occult Blood Test (by Country)
Table 9: Reimbursement of Colonoscopies and Sigmoidoscopies (by Country)
Table 10: Reimbursement of Biomarker Tests (by Country)
Table 11: Pricing Analysis for Different Test Types in Different Regions,($)
Table 12: Impact Analysis of Market Navigating Factors, 2023-2033
Table 13: Examples of Global Colorectal Cancer Screening Initiatives
Table 14: Examples of Product Launches and Approval in Asia-Pacific
Table 15: Global Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 16: Global Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 17: Pricing Analysis for Stool DNA Test in Different Regions,($)
Table 18: Pricing Analysis for Different Fecal Immunochemical Test Different Regions,($)
Table 19: Pricing Analysis for Fecal Occult Blood Test in Different Regions,($)
Table 20: Pricing Analysis for Colonoscopies and Sigmoidoscopies in Different Regions,($)
Table 21: Pricing Analysis for Biomarker Test in Different Regions,($)
Table 22: Global Colorectal Cancer Screening and Diagnostics Market (by Region), $Million, 2022-2033
Table 23: North America Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 24: North America Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 25: U.S. Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 26: U.S. Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 27: Canada Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 28: Canada Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 29: Europe Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 30: Europe Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 31: France Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 32: France Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 33: Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 34: Germany Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 35: U.K. Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 36: U.K. Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 37: Spain Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 38: Spain Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 39: Italy Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 40: Italy Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 41: Rest-of-Europe Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Unit Thousands ), 2022-2033
Table 42: Rest-of-Europe Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 43: Asia-Pacific Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 44: Asia-Pacific Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 45: China Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 46: China Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 47: India Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 48: India Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 49: Australia Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 50: Australia Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 51: Japan Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 52: Japan Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 53: South Korea Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 54: South Korea Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 55: Rest-of-Asia-Pacific Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 56: Rest-of-Asia-Pacific Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 57: Latin America Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 58: Latin America Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 59: Brazil Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 60: Brazil Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 61: Mexico Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 62: Mexico Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 63: Rest-of-Latin America Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 64: Rest-of-Latin America Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 65: Middle East and Africa Colorectal Cancer Screening and Diagnostics Market (by End User), $Million, 2022-2033
Table 66: Middle East and Africa Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 67: U.A.E. Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 68: U.A.E. Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 69: South Africa Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 70: South Africa Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033
Table 71: Rest-of-Middle East and Africa Colorectal Cancer Screening and Diagnostics Market (by Type), Test Volume (Thousands), 2022-2033
Table 72: Rest-of-Middle East and Africa Colorectal Cancer Screening and Diagnostics Market (by Type), $Million, 2022-2033

Press Release